Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Hodgkin's Lymphoma”

1,639 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,639 results

Testing effectiveness (Phase 2)WithdrawnNCT00005969
What this trial is testing

Liposomal Tretinoin in Treating Patients With Recurrent or Refractory Hodgkin's Disease

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00048555
What this trial is testing

Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Biogen 90
Not applicableUnknownNCT00295997
What this trial is testing

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Who this might be right for
Chronic Myeloproliferative DisordersKidney CancerLeukemia+4 more
University of California, San Francisco 35
Not applicableUnknownNCT04666168
What this trial is testing

Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma

Who this might be right for
Non-hodgkin's Lymphoma
Hebei Senlang Biotechnology Inc., Ltd. 200
Testing effectiveness (Phase 2)Looking for participantsNCT05907759
What this trial is testing

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

Who this might be right for
Lymphoma, Primary Effusion
National Cancer Institute (NCI) 28
Testing effectiveness (Phase 2)Study completedNCT03436862
What this trial is testing

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

Who this might be right for
Hodgkin Lymphoma
SCRI Development Innovations, LLC 37
Early research (Phase 1)Active Not RecruitingNCT03479268
What this trial is testing

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

Who this might be right for
B-Cell Prolymphocytic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell Lymphoma+15 more
City of Hope Medical Center 18
Testing effectiveness (Phase 2)Study completedNCT01281917
What this trial is testing

Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkins Lymphoma
University of Wisconsin, Madison 40
Early research (Phase 1)Study completedNCT00005946
What this trial is testing

Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
University of Maryland, Baltimore
Testing effectiveness (Phase 2)Looking for participantsNCT07439653
What this trial is testing

TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

Who this might be right for
Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
TORL Biotherapeutics, LLC 155
Large-scale testing (Phase 3)WithdrawnNCT00577161
What this trial is testing

Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL

Who this might be right for
Non-Hodgkin's Lymphoma
CTI BioPharma
Testing effectiveness (Phase 2)Study completedNCT02988466
What this trial is testing

Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT

Who this might be right for
Hematologic Malignancies
Masonic Cancer Center, University of Minnesota 78
Testing effectiveness (Phase 2)Study completedNCT04601831
What this trial is testing

'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL

Who this might be right for
Non-Hodgkin Lymphoma
University of Texas Southwestern Medical Center 14
Testing effectiveness (Phase 2)Study completedNCT02061761
What this trial is testing

Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Hematologic Neoplasms
Bristol-Myers Squibb 106
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Testing effectiveness (Phase 2)Looking for participantsNCT04390737
What this trial is testing

Evaluate the Safety and Clinical Activity of HH2853

Who this might be right for
FL LymphomaEpithelioid SarcomaPeripheral T Cell Lymphoma+1 more
Haihe Biopharma Co., Ltd. 254
Testing effectiveness (Phase 2)Looking for participantsNCT06534437
What this trial is testing

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

Who this might be right for
Non-Hodgkin Lymphoma, B-cell
Ryvu Therapeutics SA 178
Testing effectiveness (Phase 2)Study completedNCT00540007
What this trial is testing

Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Hodgkin Disease
Washington University School of Medicine 80
Early research (Phase 1)Ended earlyNCT05994157
What this trial is testing

Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Non-hodgkin Lymphoma
Y-mAbs Therapeutics 1
Testing effectiveness (Phase 2)Ended earlyNCT02572453
What this trial is testing

Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

Who this might be right for
Recurrent Anaplastic Large Cell LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Mantle Cell Lymphoma+5 more
National Cancer Institute (NCI) 25
Load More Results